Tech Company Financing Transactions
Kenta Biotech Funding Round
Kenta Biotech, operating out of Quzhou Zhejiang, raised $12 million from private investors.
Transaction Overview
Company Name
Announced On
3/12/2009
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Series B
Investors
Proceeds Purpose
The Proceed will be used for the ongoing clinical development of KBPA 101 in nosocomial pneumonia and to advance KBSA 201, a fully human IgG monoclonal antibody against methicilin-resistant Staphylococcus aureus, from preclinical into clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Donggang Industrial Park Lin Xi Lu No. 39
Quzhou Zhejiang, 324000
China
Quzhou Zhejiang, 324000
China
Phone
Website
Email Address
Overview
Kenta Biotech is focusing on the discovery and development of innovative, fully human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Franco Merckling
Chief Medical Officer
Toni Perez
Chief Scientific Officer
Michael Rudolf
Browse more venture capital transactions:
Prev: 3/12/2009: DriverSide venture capital transaction
Next: 3/12/2009: NeoMatrix venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs